Illumina (NASDAQ: ILMN) shareholders may be in for a rude surprise. Suitor Roche could be close to walking away from a $6.8 billion offer which values the gene research company’s shares at $51. The Illumina board has pressed for a much, much higher price backed by the argument that the firm’s technology could be among the most important for medical research over the coming decades.
Roche’s tender offer expires on Friday. Illumina’s share price jumped from $32 to $55 in early January after the first Roche offer was made. Investors have become increasingly pessimistic in the last week as shares have fallen to $45.
Illimina’s management will quickly have to prove that the firm is worth $51 all on its own based on earnings and a perception of future prospects
“The Next NVIDIA” Could Change Your Life
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.